RxDoctor Payments Data

Kelsi Fulda

Family · Marion, INNPI 1992409478

Payments from drug & device makers

$599in general payments, 2019–2025

Across 19 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$132
  • Axsome Therapeutics, Inc.$116
  • AstraZeneca$83
  • AbbVie$55
  • Bayer$39
  • Pharmaessentia USA Corporation$26
  • plus $149 from 9 others

What the payments were for

  • Food & beverage$599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$599 in reported general payments places this provider in the 55th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$15,051
Medicare patients
88
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$34,009
EliquisApixaban23$33,983
JardianceEmpagliflozin22$30,382
TrulicityDulaglutide14$28,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$26,934
Atorvastatin Calcium169$1,498
Albuterol Sulfate HfaAlbuterol Sulfate41$1,394
Gabapentin52$1,062
Omeprazole66$954
Levothyroxine Sodium54$823
Verapamil SrVerapamil Hcl11$819
Losartan Potassium93$757
Potassium Chloride31$711
Metoprolol Succinate62$633
Pantoprazole Sodium33$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$13$26,93418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,392 family providers in Indiana.

Other family in Marion

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →